Trial Profile
The effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults with previous smallpox vaccination
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2018
Price :
$35
*
At a glance
- Drugs ACAM 2000 (Primary) ; Smallpox vaccine
- Indications Smallpox
- Focus Adverse reactions; Pharmacodynamics
- 30 Sep 2008 Actual patient number (357) added as reported by ClinicalTrials.gov.
- 30 Sep 2008 Primary outcome added as reported by ClinicalTrials.gov.
- 30 Sep 2008 Planned end date changed from 1 Mar 2003 to 1 Oct 2003 as reported by ClinicalTrials.gov.